11 citations
,
August 2022 in “Evidence-based Complementary and Alternative Medicine” Eclipta alba leaf extract shows strong antibacterial effects against certain bacteria but not tuberculosis.
4 citations
,
October 2022 in “Microbial Cell Factories” Certain bacteria from the Citrullus colocynthis plant may be a new source of antibiotics to fight drug-resistant diseases.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
December 2025 in “Journal of Mycology and Infection” Griseofulvin effectively treats tinea capitis in infants.
48 citations
,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
1 citations
,
July 1990 in “European Journal of Pharmacology”
The document concluded that certain compounds might strongly bind to and potentially inhibit a key SARS-CoV-2 protein, but further testing is needed.
February 2026 in “International Journal of Research in Dermatology” Two adults with unusual scalp fungus symptoms were successfully treated.
2 citations
,
March 2026 in “Journal of Dermatological Treatment” JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.
37 citations
,
December 2020 in “Molecules” A new delivery system makes Curcumin more effective and safer against viruses.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
March 2017 in “Zenodo (CERN European Organization for Nuclear Research)” L. plantarum MTCC 1325 may help improve memory and cognitive functions in Alzheimer's.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
September 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Blocking CCR5 can prevent and improve hair loss in alopecia areata.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
March 2026 in “International Journal of Dermatology and Venereology” Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.
55 citations
,
December 1983 in “Acta Neurologica Scandinavica” Carbamazepine, valproate, and clonazepam can cause mild to serious side effects during long-term epilepsy treatment.
5 citations
,
January 2020 in “Skin Appendage Disorders” The nail strengthener with Pistacia lentiscus and hyaluronic acid improves brittle nails' appearance and strength.
September 2023 in “Journal of the American Academy of Dermatology” Topical tofacitinib helped a man with severe scalp condition after other treatments failed.
August 2016 in “Journal of Investigative Dermatology” Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.
1 citations
,
September 2024 in “Life” Combining fractionated CO2 laser with tacrolimus may help treat chronic alopecia areata.
May 2026 in “SKIN The Journal of Cutaneous Medicine” Baricitinib may cause low blood sugar in some patients, so careful monitoring is needed.
February 2025 in “Jurnal Kesehatan Bakti Tunas Husada Jurnal Ilmu-ilmu Keperawatan Analis Kesehatan dan Farmasi” Nanostructured Lipid Carriers can improve curcumin's effectiveness for treating hair loss.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
March 2021 in “Research Square (Research Square)” Strontium ranelate helps cartilage growth by blocking a specific cell pathway.
March 2024 in “EMBO molecular medicine” Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.
April 2026 in “Therapeutic Advances in Drug Safety” Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.
August 2019 in “Reactions Weekly” Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.
1 citations
,
October 2011 in “Hospital Pharmacy”